Based on positive clinical trial results, Seattle Genetics intends to file a marketing application for the #breastcancer drug, called tucatinib, with the FDA early next year. buff.ly/2J9CYEo
A new form of the genome-editing tool CRISPR-Cas9 appears to significantly expand the range of diseases that could be treated with the technology. buff.ly/2VYWLvv
Opinion: Although new delivery methods will help telehealth expand, they are sometimes handcuffed by varied and conflicting state and federal rules. buff.ly/2J9dBSY